BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29599339)

  • 1. Depth of
    Seder CW; Mahon B; Hennon M; Thomas M; Levea CM; Matkowskyj KA; Krishna M; Medairos R; Macke RA; Basu S; Blasberg JD
    Anticancer Res; 2018 Apr; 38(4):2195-2200. PubMed ID: 29599339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duplicated muscularis mucosae invasion has similar risk of lymph node metastasis and recurrence-free survival as intramucosal esophageal adenocarcinoma.
    Estrella JS; Hofstetter WL; Correa AM; Swisher SG; Ajani JA; Lee JH; Bhutani MS; Abraham SC; Rashid A; Maru DM
    Am J Surg Pathol; 2011 Jul; 35(7):1045-53. PubMed ID: 21602659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the T2 substage in patients with esophageal squamous cell carcinoma.
    Duan J; Deng T; Ying G; Zhang H; Zhou L; Bai M; Li H; Ba Y
    Dis Esophagus; 2017 Apr; 30(4):1-7. PubMed ID: 28375473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are endoscopic therapies appropriate for superficial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens.
    Sepesi B; Watson TJ; Zhou D; Polomsky M; Litle VR; Jones CE; Raymond DP; Hu R; Qiu X; Peters JH
    J Am Coll Surg; 2010 Apr; 210(4):418-27. PubMed ID: 20347733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinoma.
    Liu L; Hofstetter WL; Rashid A; Swisher SG; Correa AM; Ajani JA; Hamilton SR; Wu TT
    Am J Surg Pathol; 2005 Aug; 29(8):1079-85. PubMed ID: 16006804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.
    Barbetta A; Schlottmann F; Nobel T; Sewell DB; Hsu M; Tan KS; Gerdes H; Shah P; Bains MS; Bott M; Isbell JM; Jones DR; Molena D
    Ann Thorac Surg; 2018 Jul; 106(1):172-177. PubMed ID: 29627387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma.
    Lewis JT; Wang KK; Abraham SC
    Am J Surg Pathol; 2008 Apr; 32(4):566-71. PubMed ID: 18300796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic mucosal resection as a staging technique to determine the depth of invasion of esophageal adenocarcinoma.
    Maish MS; DeMeester SR
    Ann Thorac Surg; 2004 Nov; 78(5):1777-82. PubMed ID: 15511474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duplication of the muscularis mucosae in Barrett esophagus: an underrecognized feature and its implication for staging of adenocarcinoma.
    Abraham SC; Krasinskas AM; Correa AM; Hofstetter WL; Ajani JA; Swisher SG; Wu TT
    Am J Surg Pathol; 2007 Nov; 31(11):1719-25. PubMed ID: 18059229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment.
    Altorki NK; Lee PC; Liss Y; Meherally D; Korst RJ; Christos P; Mazumdar M; Port JL
    Ann Surg; 2008 Mar; 247(3):434-9. PubMed ID: 18376186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens.
    Leers JM; DeMeester SR; Oezcelik A; Klipfel N; Ayazi S; Abate E; Zehetner J; Lipham JC; Chan L; Hagen JA; DeMeester TR
    Ann Surg; 2011 Feb; 253(2):271-8. PubMed ID: 21119508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. pT2 Adenocarcinoma of the esophagus: early or advanced cancer?
    Metzger R; Lorenz D; Gockel I; Origer J; Plum PS; Junginger T; Drebber U; Hansen T; Krümpelmann K; Fisseler-Eckhoff A; Lang H; Hölscher AH; Bollschweiler E
    Ann Thorac Surg; 2013 Nov; 96(5):1840-5. PubMed ID: 23987902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramucosal esophageal adenocarcinoma: primum non nocere.
    Li Z; Rice TW; Liu X; Goldblum JR; Williams SJ; Rybicki LA; Murthy SC; Mason DP; Raymond DP; Blackstone EH
    J Thorac Cardiovasc Surg; 2013 Jun; 145(6):1519-24, 1524.e1-3. PubMed ID: 23158254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.
    Tachezy M; Tiebel AK; Gebauer F; Kutup A; Tharun L; Pantel K; Izbicki JR; Vashist YK
    Histol Histopathol; 2014 Nov; 29(11):1467-75. PubMed ID: 24819775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.
    Dittrick GW; Weber JM; Shridhar R; Hoffe S; Melis M; Almhanna K; Barthel J; McLoughlin J; Karl RC; Meredith KL
    Ann Surg Oncol; 2012 May; 19(5):1678-84. PubMed ID: 22045465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.